These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 21342412

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
    Rosenstock J, Gross JL, Aguilar-Salinas C, Hissa M, Berglind N, Ravichandran S, Fleming D.
    Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
    Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, Montanaro M, Fisher SA.
    Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH, Charbonnel B, Li J, Donovan M, Fleming D, Iqbal N.
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
    Hollander PL, Li J, Frederich R, Allen E, Chen R, CV181013 Investigators.
    Diab Vasc Dis Res; 2011 Apr; 8(2):125-35. PubMed ID: 21562064
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
    Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J.
    Diabetes Obes Metab; 2019 Apr; 21(4):883-892. PubMed ID: 30499237
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial.
    Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I.
    Diabetes Res Clin Pract; 2011 Nov; 94(2):217-24. PubMed ID: 21871686
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study.
    Gu W, Liang L, Wang S, Wang Y, Wu Y, Tian J, Yang G, Piao C, Li Y, Yin J, Xin X, Tan X, Ning G, Wang W, SUNSHINE Study Group.
    J Diabetes; 2016 Nov; 8(6):809-815. PubMed ID: 26676908
    [Abstract] [Full Text] [Related]

  • 18. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
    Matthaei S, Aggarwal N, Garcia-Hernandez P, Iqbal N, Chen H, Johnsson E, Chin A, Hansen L.
    Diabetes Obes Metab; 2016 Nov; 18(11):1128-1133. PubMed ID: 27403645
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial.
    Gu T, Ma J, Zhang Q, Zhu L, Zhang H, Xu L, Cheng J, Shi B, Li D, Shao J, Sun Z, Zhong S, Bi Y, Zhu D.
    Diabetes Obes Metab; 2019 Apr; 21(4):939-948. PubMed ID: 30520221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.